Drug Search Results
More Filters [+]

Oglemilast

Alternative Names: oglemilast
Latest Update: 2019-09-19
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: PDE4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oglemilast

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Chronic Obstructive Pulmonary Disease|Asthma|Asthma, Exercise-Induced

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

GRC 3886-201

P2

Unknown status

Asthma

2009-12-01

GRC-MD-50

P2

Completed

Chronic Obstructive Pulmonary Disease

2009-05-15

GRC-MD-03

P2

Completed

Asthma

2006-12-01

GRC-MD-01

P2

Completed

Asthma, Exercise-Induced

2006-10-01

Recent News Events

Date

Type

Title